Skip to content

Enterprise value at other companies

Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$5.33B+162%
Arrowhead Research logo
Arrowhead ResearchARWR
$8.7B+418%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$12.92B+175%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$16.77B+178%
TG Therapeutics logo
TG TherapeuticsTGTX
$5.62B-11.1%
Alkermes logo
AlkermesALKS
$7.12B+41.2%

Other financials

Income statement

See full
Revenue$132.9M+4,158%
Gross profit$1.6M+6.5%
Operating income$61.5M+274%
Net income$52.9M+238%
EPS (diluted)$0.52+216%

Balance sheet

See full
Cash & equivalents$222.8M+31.2%
Total debt$7.0M+1.5%
Total equity$108.6M+118%
Total assets$401.5M+76.6%

Cash flow

See full
Operating cash flow$53.0M+273%
CapEx$2.8M+758%
Free cash flow$50.2M+262%

Valuation

See full
Market cap$6.32B+164%
P/S21.9×-147×

Profitability

See full
Gross margin58.1%-18.7pp
Operating margin-155%-68.1pp
Net margin-176.2%-76.4pp
FCF margin-150.7%-64.4pp

Returns & leverage

See full
Return on equity-181%+57.4pp
Debt / equity0.1×-0.1×
Current ratio2.2×-0.7×

Where this comes from

Calculated from Liquidia Corporation’s reported figures.

The official record: Liquidia Corporation’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Liquidia Corporation's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Liquidia Corporation's enterprise value?
Liquidia Corporation (LQDA) reported enterprise value of $3.11B in Q1 2026.
How has Liquidia Corporation's enterprise value changed year-over-year?
Liquidia Corporation's enterprise value increased by 183.9% year-over-year, from $1.1B to $3.11B.
What is the long-term trend for Liquidia Corporation's enterprise value?
Over 4 years (2020 to 2024), Liquidia Corporation's enterprise value has grown at a 67.4% compound annual growth rate (CAGR), from $105.16M to $825.85M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.